$MTVA Up 41%! 🚀 🔹 MetaVia catching fire as GLP-1 obesity names continue to attract major attention 📈 🔹 Company is advancing DA-1726, a GLP-1/glucagon dual a

$MTVA Up 41%! 🚀 🔹 MetaVia catching fire as GLP-1 obesity names continue to attract major attention 📈 🔹 Company is advancing DA-1726, a GLP-1/glucagon dual agonist targeting obesity + metabolic disease 🔥 🔹 Recent data showed strong weight-loss signals, improved glucose control, and positive liv…